Investors > News Releases
Jun 28, 2018
BRACAnalysis® CDx Identifies Patients Who Respond to Lynparza® in SOLO-1 Study
Jun 21, 2018
Top-Five National Payer Issues Positive Coverage Decision for Myriad’s Prolaris® Test for Prostate Cancer
Jun 18, 2018
Myriad’s BRACAnalysis CDx® Supplementary PMA Accepted by FDA for Review as a Companion Diagnostic for Talazoparib in Metastatic Breast Cancer
Jun 06, 2018
Crescendo Bioscience Announces Four Studies with Vectra® DA Will Be Featured at the 2018 European League Against Rheumatism Annual Meeting
Pipeline
Jun 01, 2018
Myriad Genetics Presents Second Pivotal Validation Study for riskScore™ Test at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting
Pipeline
May 31, 2018
Myriad Genetics to Present at Two Upcoming Investor Conferences
Corporate
May 31, 2018
GeneSight® Guided Treatment Significantly Improves Outcomes for Patients with Major Depression Treated in the Primary Care Setting
Products
May 28, 2018
Myriad Genetics Signs Definitive Agreement to Acquire Counsyl, Inc.
Corporate
May 23, 2018
Myriad Announces Seven New Payer Coverage Decisions for Prolaris®
Products
May 15, 2018
Myriad Genetics to Present Eight Studies at the 2018 American Society of Clinical Oncology Annual Meeting
Pipeline
May 08, 2018
Myriad Genetics Reports Fiscal Third-Quarter 2018 Financial Results
Financial
May 07, 2018
Landmark Study Shows GeneSight® Test Led to Significant Improvement in Mental Health Outcomes for Patients with Major Depressive Disorder
Products
May 04, 2018
Myriad Genetics to Present Five Studies at the Seventh International Symposium on Hereditary Breast and Ovarian Cancer
Pipeline
May 02, 2018
Myriad Genetics Named to Forbes 2018 List of America's Best Midsize Employers
Corporate
Apr 27, 2018
Myriad Genetics to Present at Two Upcoming Healthcare Conferences
Corporate